Following the reverse stock split, the company's common stock will continue to trade on the Nasdaq Capital Market under the symbol "BTAI" with the new CUSIP number, 09075P204. The reverse stock split ...

(RTTNews) - BioXcel Therapeutics, Inc. (BTAI), Thursday announced a reverse stock split of 1-for-16 to regain compliance with the minimum bid price requirement for continued listing on the Nasdaq ...

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with ...

BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a pharmaceutical company with a market capitalization of $14.83 million, announced today the implementation of a 1-for-16 reverse stock split of its common ...

NEW HAVEN, Conn. - BioXcel Therapeutics, Inc. (NASDAQ:BTAI), a biopharmaceutical company focused on artificial ...

Equities research analysts at HC Wainwright raised their FY2024 EPS estimates for shares of BioXcel Therapeutics in a ...

BioXcel Therapeutics, Inc. conducted a special meeting of stockholders to decide on crucial matters. The meeting saw the ...

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE ...

"Our pioneering spot pricing program is a testament to Plug's commitment to customer-centric innovation,” said Andy Marsh, ...